CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2023 Results Conference Call March 11, 2024 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer and Chairman Conference Call Participants Joe Catanzaro - Piper Sandler Malcolm Kuno - JPMorgan Operator Good day, and thank you for standing by. Welcome to the CytomX Therapeutics Fourth Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen only-mode. ...

CytomX Therapeutics (CTMX) came out with quarterly earnings of $0.01 per share, missing the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.42 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.17 per share when it actually produced earnings of $0.04, delivering a surprise of 123.53%.Over the last four quarter ...

- CX-904 (EGFRxCD3 T-cell engager) initial Phase 1a dose escalation data in solid tumors anticipated in the 2nd half of 2024 - - CX-2051 (EpCAM ADC) Phase 1 clinical study initiation in solid tumors, including colorectal cancer (CRC) anticipated in the 1st half of 2024 - - CX-801 (IFNα2b) Phase 1 clinical study initiation in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma anticipated in 1st half of 2024 -   - Management to hold conference call today at 5 p.m. EDT / 2 p.m. ...

Pediatric Studies Biologic manufacturers and other entities involved in the manufacture and distribution of approved therapeutic products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and some state agencies for compliance with cGMPs and other laws. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive and record-keeping requi ...

Exhibit 99.1 CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update SOUTH SAN FRANCISCO, Calif., March 11, 2024 – CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update. "2023 was a year of sustained execution across our pipeline, highlighted by the continued progress of CX-904 in Phase 1 dose escalation and the parallel advancement of CX-2051 and ...

CytomX Therapeutics (CTMX) is expected to report fourth-quarter and full-year 2023 results soon. In the last reported quarter, the company beat earnings expectations by 123.53%.Factors to NoteCytomX does not have any marketed product. Investor focus on the fourth-quarter 2023 earnings call will be on updates regarding key cancer immunotherapeutic candidates, CX-904 and BMS-986288.CX-904 is an EGFR-CD3 T-cell engager, developed in partnership with Amgen (AMGN) , while BMS-986288 is a non-fucosylated CTLA-4 t ...

- Initiation of CX-2051 Phase 1 clinical study in EpCAM positive tumors including colorectal cancer anticipated in 1H 2024 - - Initiation of CX-801 Phase 1 clinical study in solid tumors including melanoma, renal, and head and neck squamous cell carcinoma also anticipated in 1H 2024 - SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of conditionally activated, localized biologics, today announced that it has received clearance from ...

Financial Data and Key Metrics Changes - For Q3 2023, revenue was $26.4 million, compared to $11.1 million for the same period in 2022, indicating a significant increase [45] - Operating expenses for Q3 2023 were $23.3 million, with R&D expenses decreasing by $14 million to $16.4 million compared to the same period in 2022 [45] - Overall cash burn in Q3 was $16.8 million, down from $33.9 million in the equivalent period of 2022, reflecting improved capital allocation and cash management [18] Business Line Data and Key Metrics Changes - CX-904 is advancing through Phase 1 with initial data expected in the first half of 2024, focusing on EGFR positive tumors [5][46] - CX-2051 is on track for IND filing by the end of 2023, with Phase 1 initiation planned for 2024, particularly targeting colorectal cancer [5][46] - CX-801, a masked version of Interferon Alpha-2b, is also on track for IND filing by the end of 2023, with clinical initiation expected in 2024 [15][46] Market Data and Key Metrics Changes - The company has partnerships with major players like Moderna, Regeneron, Astellas, Amgen, and BMS, which enhance its platform and provide non-dilutive financing [6][42] - The company has over 15 active R&D programs, with significant potential for milestone payments from partnerships [42] Company Strategy and Development Direction - The company is focused on the discovery and development of novel cancer medicines using its Probody Therapeutic platform, aiming to localize potent biologics into diseased tissue [4] - The strategy includes a disciplined approach to capital allocation and maintaining a strong financial position amid a challenging biotech environment [18][16] - The pipeline includes T-cell engagers, ADCs, and cytokines, with a focus on delivering value-creating milestones in 2024 and 2025 [20] Management's Comments on Operating Environment and Future Outlook - Management highlighted the strong fundamentals of the company and its positioning for future growth despite external challenges in the biotech sector [4] - The company anticipates multiple inflection points over the next 12 to 18 months as it continues its work in oncology R&D [21] Other Important Information - The company expects its current cash resources to fund operations into the second half of 2025, without assuming additional milestones from partnerships [18] - Management emphasized the importance of partnerships in expanding the reach of their technology and providing financial support [33] Q&A Session Summary Question: Expectations for upcoming data in the first half of next year - Management indicated that initial data from Phase 1a for CX-904 is expected in the first half of 2024, with decisions on expansion cohorts to follow [23][50] Question: Specific tumor types of interest for CX-801 - Management noted that CX-801 has shown clinical activity in several tumor types, including melanoma and renal cancers, and will focus on immune-competent tumors [54] Question: Update on collaborations with Astellas and Regeneron - Management expressed excitement about the partnerships, highlighting ongoing work in bispecific immunotherapies and the potential for significant future developments [62]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commis ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2023 Results Conference Call August 8, 2023 5:00 PM ET Company Participants Chris Ogden - Senior Vice President, Finance and Accounting Sean McCarthy - Chief Executive Officer Conference Call Participants Roger Song - Jefferies Priyanka Grover - JP Morgan Dipesh Patel - H.C. Wainwright Operator Good day, and welcome to the CytomX Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time all participants are in a listen-only mode. After the sp ...